Maia page

DARZALEX® may help you live longer without your multiple myeloma getting worse

DARZALEX® in combination with Revlimid® (lenalidomide) + dexamethasone (DRd) was proven effective in a clinical study of adults who were newly diagnosed with multiple myeloma and cannot receive a stem cell transplant.*

DARZALEX® + lenalidomide + dexamethasone increased the time most patients lived without their disease getting worse

of patients treated with DARZALEX® + Rd (n=368) lived without their disease getting worse vs 61% of patients treated with Rd alone (n=369).  

At a median follow-up of 28 months.


More patients responded to DARZALEX® in combination with Rd vs Rd alone

nine out of ten responded to DARZALEX<sup>®</sup> in combination with Rd vs Rd alone

93% of patients responded to DARZALEX® + Rd vs 81% of patients treated with Rd alone.

*The main goals of the study were to measure the length of time patients lived without their multiple myeloma getting worse and how many people responded to treatment.

How DARZALEX® works

DARZALEX® is not chemotherapy. It is an immunotherapy that works with your immune system.

DARZALEX® targets a specific protein on multiple myeloma cells and may also affect normal cells with this protein. DARZALEX® can cause serious side effects, including infusion reactions and decreases in blood cell counts. See Important Safety Information below.

Learn more about how DARZALEX® works.


Please see Important Product Information.

Revlimid® is a registered trademark of Celgene Corporation.